Division of Cardiology, Department of Pediatrics, Washington University in St. Louis School of Medicine, ST Louis, Missouri, USA.
Division of Pediatric Cardiology, University of Iowa Children's Hospital, Iowa City, Iowa, USA.
Catheter Cardiovasc Interv. 2020 Nov;96(6):1277-1286. doi: 10.1002/ccd.29248. Epub 2020 Sep 9.
Coarctation of the aorta represents 5-8% of all congenital heart disease. Although balloon expandable stents provide an established treatment option for native or recurrent coarctation, outcomes from transverse arch (TAO) stenting, including resolution of hypertension have not been well studied. This study aims to evaluate immediate and midterm results of TAO stenting in a multi-center retrospective cohort.
TAO stenting was defined as stent placement traversing any head and neck vessel, with the primary intention of treating narrowing in the transverse aorta. Procedural details, complications and medications were assessed immediately post procedure, at 6 month follow-up and at most recent follow-up.
Fifty-seven subjects, 12 (21%) native, and 45 (79%) surgically repaired aortic arches, from seven centers were included. Median age was 14 years (4 days-42 years), median weight 54 kg (1.1-141 kg). After intervention, the median directly measured arch gradient decreased from 20 mmHg (0-57 mmHg) to 0 mmHg (0-23 mmHg) (p < .001). The narrowest arch diameter increased from 9 mm (1.4-16 mm) to 14 mm (2.9-25 mm) (p < .001), with a median increase of 4.9 mm (1.1-10.1 mm). One or more arch branches were covered by the stent in 55 patients (96%). There were no serious adverse events. Two patients warranted stent repositioning following migration during deployment. There were no late complications. There were 8 reinterventions, 7 planned, and 1 unplanned (6 catheterizations, 2 surgeries). Antihypertensive management was continued in 19 (40%) at a median follow-up of 3.2 years (0.4-7.3 years).
TAO stenting can be useful in selected patients for resolution of stenosis with minimal complications. This subset of patients are likely to continue on antihypertensive medications despite resolution of stenosis.
主动脉缩窄占所有先天性心脏病的 5-8%。虽然球囊扩张支架为原发性或复发性主动脉缩窄提供了一种既定的治疗选择,但对于弓部(TAO)支架置入术的结果,包括高血压的缓解情况,尚未得到很好的研究。本研究旨在评估多中心回顾性队列中 TAO 支架置入术的即刻和中期结果。
TAO 支架置入术定义为支架穿过任何头颈部血管,主要目的是治疗升主动脉狭窄。评估即刻术后、6 个月随访和最近随访时的手术细节、并发症和药物治疗情况。
来自七个中心的 57 名患者(12 名(21%)为原发性,45 名(79%)为主动脉弓部修复)纳入本研究。中位年龄为 14 岁(4 天-42 岁),中位体重为 54kg(1.1-141kg)。干预后,直接测量的弓部梯度中位数从 20mmHg(0-57mmHg)降至 0mmHg(0-23mmHg)(p<.001)。最窄弓部直径从 9mm(1.4-16mm)增加到 14mm(2.9-25mm)(p<.001),中位数增加 4.9mm(1.1-10.1mm)。55 名患者(96%)的一个或多个弓部分支被支架覆盖。无严重不良事件发生。有 2 名患者在支架展开时发生迁移,需要重新定位支架。无晚期并发症。有 8 例再介入,7 例为计划性,1 例为非计划性(6 次导管治疗,2 次手术)。在中位随访 3.2 年(0.4-7.3 年)时,19 名患者(40%)继续使用抗高血压药物治疗。
TAO 支架置入术在治疗狭窄方面可能对有选择的患者有用,且并发症最小。尽管狭窄缓解,但这部分患者可能继续服用抗高血压药物。